Welcome to the Cytokine-Based Cancer Immunotherapies Summit Boston
The therapeutic opportunities presented by the synergistic effect of T-cell based immunotherapies and cytokine-based interventions is well documented in pre-clinical models. However, due to systemic toxicity and the lack of durable efficacy responses (in lower doses) in clinical trials, drug developers are faced with the challenges of how to expand the therapeutic index of cytokine-based cancer immunotherapies. This summit focuses on the raw challenges holding back the space: how the leaders in the field are addressing barriers in the toxicity, dosage, delivery, specificity, combinatorial and translational issues which are driving investment and resources in this space.
Delve into cytokine research beyond oncology, understand application & translation in inflammatory diseases with AbbVie & University of Dundee
Uncover the therapeutic potential of cytokines through methods of overcoming toxicity with Merck & Co. , John Hopkins, TeneoBio & Xilio Therapeutics
Optimize application through successful cytokine dosing & delivery with Philogen, MD Anderson & Ankyra Therapeutics
Discover the clinical results & what these mean for the translatability of pre-clinical data and the future of this space with Roche, Sanofi & BioNTech
Network In Person with all attendees, ask your burning questions, build connections and fully immerse yourself in the world of cytokines